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Abstract
Polycystin signaling is likely to be regulated by phosphorylation. While a number of potential protein kinases and their
target phosphorylation sites on polycystin-1 have been identified, the corresponding phosphatases have not been
extensively studied. We have now determined that polycystin-1 is a regulatory subunit for protein phosphatase-1a (PP1a).
Sequence analysis has revealed the presence of a highly conserved PP1-interaction motif in the cytosolic, C-terminal tail of
polycystin-1; and we have shown that transfected PP1a specifically co-immunoprecipitates with a polycystin-1 C-tail
construct. To determine whether PP1a dephosphorylates polycystin-1, a PKA-phosphorylated GST-polycystin-1 fusion
protein was shown to be dephosphorylated by PP1a but not by PP2B (calcineurin). Mutations within the PP1-binding motif
of polycystin-1, including an autosomal dominant polycystic kidney disease (ADPKD)-associated mutation, significantly
reduced PP1a-mediated dephosphorylation of polycystin-1. The results suggest that polycystin-1 forms a holoenzyme
complex with PP1a via a conserved PP1-binding motif within the polycystin-1 C-tail, and that PKA-phosphorylated
polycystin-1 serves as a substrate for the holoenzyme.
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Introduction
Phosphorylation is a common post-translational modification of
proteins that affects their structure and ability to interact with
other proteins, and thus ultimately their function. As such,
understanding the functions of protein kinases and phosphatases
is of critical importance to cellular biology. Protein phosphatase-1
(PP1) is a widely expressed serine/threonine phosphatase that
regulates numerous cellular functions including ion channel
activity, cytoskeletal organization, cell cycle progression, and gene
transcription [1,2]. The broad substrate specificity of PP1 is
dictated by its interactions with a wide range of regulatory proteins
[3]. These ‘‘holoenzyme’’ complexes can dephosphorylate single
or multiple substrates and are themselves subject to being
regulated by events such as post-translational modification or
binding of additional accessory proteins [1,2,4]. The mammalian
genome contains three genes encoding four isoforms of PP1 (a, b,
c1, and c2) that are approximately 90% identical. However,
differences within their N- and C-termini affect binding to
regulatory proteins and are important for enzyme specificity [2].
PP1-binding regulatory proteins are structurally and function-
ally diverse. Most regulatory proteins contain an ‘‘RVxF’’ motif
(where R can be arginine or lysine and x = any amino acid) that
binds within a hydrophobic groove located far away from the
active site of the phosphatase [5]. The motif ‘‘FxxBxB’’ (where B
= basic) has also been identified as a PP1-binding domain [6,7];
and recently additional regulatory protein-binding regions within
PP1 have been identified [8]. While all PP1-regulatory proteins
localize the phosphatase to specific regions within the cell, some
also directly affect the catalytic activity of the enzyme.
Autosomal dominant polycystic kidney disease (ADPKD) is
a common genetic disorder affecting 1:400–1,000 individuals and
leading to ,10% of all end-stage renal disease [9,10]. The
hallmark of ADPKD is the presence of many fluid-filled renal
cysts. Proliferation and expansion of these cysts leads to the
progressive loss of renal function, with roughly half of the disease
population undergoing renal failure by the sixth decade of life
[11]. Extrarenal manifestations include hypertension, cardiac
hypertrophy, hepatic and pancreatic cysts, and cerebral aneurysms
[12,13].
Mutations in either PKD1 or PKD2 cause ADPKD, suggesting
that the protein products of these genes, polycystin-1 (PC1) and
polycystin-2 (PC2) are functionally linked. Indeed, PC2 interacts
with PC1 via a probable coiled-coil domain, and disruption of this
interaction is thought to be sufficient to cause PKD [14]. PC2
forms a non-selective, calcium permeable cation channel, and is
thought to regulate intracellular calcium levels in response to
mechanical stimulation, cell adhesion, or cell surface receptor
activation [15]. PC1 is a membrane-associated protein with a large
N-terminal extracellular domain of about 3,000 amino acids, 11
transmembrane domains, and a C-terminal cytosolic domain of
about 200 amino acids [16]. PC1 has been implicated in the
regulation of a number of cellular pathways, including hetero-
trimeric G protein, nuclear factor of activated T-cells (NFAT), AP-
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e367981, b-catenin, mTOR, and intracellular calcium signaling
[17,18,19]. However, the mechanism(s) by which PC1 is able to
control such diverse signaling events remains unclear.
In the current study, we demonstrate that PC1 contains
a conserved RVxF motif, that PP1a interacts with and depho-
sphorylates PC1, and that PC1 mutations within the RVxF motif,
including an ADPKD-associated mutation, block PP1a-mediated
dephosphorylation. Our results suggest that PC1 and PP1a
interact to form a holoenzyme complex. We speculate that this
complex may regulate certain aspects of PC1-mediated signaling.
Materials and Methods
Plasmids
pBlueScript was from Stratagene. pKHA3-PP1a was generously
provided by David L. Brautigan and was described previously
[20]. pcDNA1.1/AMP IL2-0 contains an EcoRI fragment
encoding the N-terminal 269 amino acids of the a-chain of the
IL2 receptor (derived from pXS Tac Glut4*; generously provided
by Nat Wolins; *a BglII site has been introduced in this construct,
leading to the mutation of amino acids 238–239 from EY to DL)
subcloned into pcDNA1.1/AMP (Invitrogen). pcDNA1.1/AMP
IL2-fusions were produced by subcloning EcoRI-NotI Pkd1
fragments encoding HT193,H A 74, and AT120 (see Figure 1) in-
frame with the IL2 receptor encoding portion of pcDNA1.1/AMP
IL2-0. The complete coding sequence and 39 UTR of IL2-HT193
used in these studies is shown in Figure S1A. The HA74 and AT120
fragments were produced by PCR amplification with their
respective forward and reverse primer pairs (Figure S1B).
pGEX4T1-HT193 and -HA74 were described previously [17]. To
produce the human (h) GST-polycystin-1 fusion protein construct,
pGEX4T1-hHT193, the region encoding the C-terminal 193
amino acids and stop codon of human PKD1 was PCR-amplified
using primers hHT-forward and AT-reverse (Figure S1B) and
cloned into the EcoRI and NotI sites of pGEX4T1 (GE
Healthcare). All mutations were introduced by QuikChange or
QuikChange II Site-Directed Mutagenesis Kits (Stratagene) using
complementary mutagenic primer pairs (primer sequences avail-
able upon request) into pcDNA1.1/AMP IL2-HT193, pGEX4T1-
HT193, pGEX4T1-hHT193, and other mPkd1 plasmids [21]. All
these mutated sequences (except Q4215P) were subcloned as
needed into the pcDNA1.1/AMP or GEX4T1 plasmids using
available restriction sites. To produce pGEX4T1-HT193 Q4215P,
mouse Pkd1 sequence containing the relevant mutation was PCR-
amplified using primers HA-forward and AT-reverse. The product
was digested with SacI and NotI, and used to replace the wild-type
SacI/NotI fragment of pGEX4T1-HT193. All mutations were
verified by DNA sequencing. Mutant sequences are shown in
Figure S1C. sIg-0 and -HT193 construction was described
previously [21]. Detailed descriptions of all cloning steps are
available upon request.
Fusion Protein Purification
BL21(DE3) bacteria were grown in LB with 50 mg/ml
ampicillin. Overnight cultures were diluted 1:40 and grown at
37uC, 250 RPM for 1.5 h, then an additional 1.5 h at 20–25uC,
250 RPM before inducing with 0.5 mM IPTG for 2 h at 20–
25uC, 250 RPM. Cell pellets were harvested by centrifugation
(3,0006g, 10 min, 4uC) and stored at 280uC. Cells were lysed in
ice cold PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4) containing 10% glycerol and 1 mM
DTT (PBS wash buffer) in a French Press. Triton X-100 was
added to 0.1% and the lysates were clarified twice by centrifu-
gation (12,0006g, 15 min, 4uC). Supernatants were then mixed
with glutathione (GSH)-Sepharose beads (approximately 0.5 ml
per 400 ml bacterial culture) pre-washed in PBS wash buffer with
0.1% Triton X-100, and incubated for 1 h with gentle agitation.
Bound proteins were washed four times with 35 ml PBS wash
buffer, and fusion proteins were eluted with four 0.5 ml aliquots of
50 mM Tris-HCl, pH 7.5 containing 5 mM reduced glutathione.
Glycerol was added to a final concentration of 15% and the fusion
proteins were aliquoted and stored at 280uC.
Cell Culture and Transient Transfection
293T cells (ATCC) were maintained in 5% CO2 at 37uCi n1 6
DMEM with L-glutamine, sodium pyruvate, and 4.5 g/L glucose
(Cellgro) supplemented with 10% heat-inactivated fetal calf serum
and 10,000 units penicillin/10 mg streptomycin per liter. Cells
were transiently transfected by a modified calcium phosphate
protocol as described previously [22].
Immunoprecipitation
Following transient transfection, cells were washed twice in ice-
cold DPBS (Cellgro), scraped in IP lysis buffer (150 mM NaCl,
10 mM Tris-HCl pH 7.5, 2 mM EDTA, 1% Triton X-100, 0.5%
NP40, 1 mM sodium orthovanadate, 25 mM glycerol-2-phos-
phate, 25 mM NaF) containing protease inhibitors PMSF
(0.2 mM) and 1 ml/ml protease cocktail inhibitor (P8340, Sigma),
and rotated for 30 min at 4uC. Lysates were clarified by
centrifugation (14,0006g, 5 min, 4uC). Protein concentration
was determined with the BCA Protein Assay Kit (Pierce), and
equivalent amounts of protein were rotated at 4uC with agarose-
conjugated HA-probe (F-7; Santa Cruz Biotech) or protein A/G+
agarose pre-washed in IP lysis buffer plus protease inhibitors. After
2 h, bound proteins were washed six times in IP lysis buffer
containing 300 mM NaCl, then boiled 4 min in SDS-PAGE
sample buffer, resolved by SDS-PAGE, and electrophoretically
transferred to PVDF.
Immunoblotting
PVDF membranes were blocked in TBS/T buffer containing
5% dry milk and 10 mM NaN3, then probed with various
antibodies diluted in TBS (20 mM Tris-HCl, pH 8.0, 548 mM
NaCl) with 0.05% Tween-20, 5% dry milk, and 10 mM NaN3.
Membranes were washed, then probed with secondary antibodies
diluted in TBS with 0.05% Tween-20 and 5% dry milk.
Membranes were washed, then incubated 5 min in horseradish
peroxidase (HRP) developing buffer (equal parts 131 mMp -
coumaric acid, 4.1 mM luminol in 0.1 M Tris-HCl, pH 9.0, and
2% stable peroxide substrate {Pierce}in 0.1 M Tris-HCl, pH 9.0
mixed immediately prior to use) and exposed to film or imaged
using a Fluor-S
TM MultiImager (BioRad). Anti-human IgG blots
were developed as described previously [23]. Antibody dilutions
were as follows: PC1 antibody A19 [24] - 1:10,000; PP1a (C-19;
Santa Cruz Biotechnology) - 1:200; GST (Pharmacia) - 1:1,000;
HA (F-7, Santa Cruz Biotechnology) - 1:500; Goat Anti-Mouse
HRP (BioRad) - 1:5,000; Goat Anti-Rabbit HRP (BioRad) -
1:10,000, Rabbit Anti-Goat HRP (Sigma) - 1:5,000; Goat Anti-
human IgG Fc-alkaline phosphatase conjugated antibody (Jackson
Immunoresearch) - 1:10,000. To re-probe, membranes were
washed twice for 5 min in 0.2 M NaOH, rinsed in TBS, then re-
blocked.
Protein Phosphorylation and Dephosphorylation
Purified fusion proteins were adsorbed to GSH-Sepharose beads
pre-washed in PKA buffer (40 mM Tris-HCl pH 7.4, 20 mM
magnesium acetate) and phosphorylated with ,190 units/ml
A PC1-PP1 Holoenzyme Complex
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protein kinase (Promega) in PKA buffer with 0.2 mM ATP and
50 mCi/ml [c-
32P]ATP, 3,000 Ci/mmol (PerkinElmer). Bound,
radio-labeled proteins were washed twice in ice-cold PP1 or PP2B
buffer (PP1:50 mM HEPES, pH 7.2, 10 mM MgCl2,1 m M
MnCl2, 1 mM DTT, 0.1% BSA; PP2B: 50 mM Tris-HCl,
pH 7.4, 1 mM NiCl2, 0.05% BSA) containing 2 mM ATP, twice
in ice-cold phosphatase buffer, then incubated with ,1.8 units/ml
purified, recombinant PP1a (Millipore) or PP2B (Promega) and
10 mg/ml calmodulin (Upstate). Reactions were terminated by the
addition of 66SDS-PAGE sample buffer and held on dry ice until
being boiled 4 min and resolved by SDS-PAGE. Proteins were
electrophoretically transferred to PVDF, and
32P incorporation
was detected by autoradiography or phosphorimaging using
a PhosphorImager SI (Molecular Dynamics) and Typhoon 9410
Variable Mode Imager (Amersham Biosciences).
Quantification
Protein band intensity was quantified following immunoblotting
and
32P incorporation was quantified following phosphorimaging
using Quantity One software version 4.2.1 (BioRad).
Statistics
Data are means 6 SE. Unless noted otherwise, statistical
significance was determined by one-way ANOVA and Student-
Newman-Keuls (S-N-K) posttest for multiple comparisons or
unpaired t-test for comparisons between control and experimental
groups.
Results
PC1 interacts with PP1a
Sequence analysis of the C-terminal cytosolic tail of mouse PC1
revealed the presence of three highly conserved putative PP1-
binding motifs (RVxF or FxxBxB) [1,6] (Figure 1A, boxed residues
and up arrows). These sequences lie in a 23-amino acid region that
is within 15 amino acids of a conserved serine residue (asterisk at
S4159) that we had previously determined to be the major site of
PKA phosphorylation in the C-terminal tail of mouse PC1 [24].
The putative PP1-binding motifs lie in the most highly conserved
region of the protein [17] and overlap with the G protein
activation domain as well as a region thought to function as
a nuclear localization signal for a C-tail proteolytic cleavage
fragment [25]. The high conservation of this region suggests that it
is vital for PC1 function, which is supported by the presence of
disease-associated mutations in this region of the protein [26].
To determine whether PC1 can interact with PP1, 293T cells
were transfected with plasmids encoding HA epitope-tagged PP1a
and the C-terminal, cytosolic 193 amino acids of mouse PC1 fused
to the extracellular and transmembrane portion of the IL2
receptor (IL2-HT193, Figure 1B). Cell lysates were immunopreci-
pitated with anti-HA antibodies, and co-precipitating proteins
were detected by SDS-PAGE and immunoblotting. As can be seen
in Figure 2,
HAPP1a readily co-precipitated the PC1 IL2-HT193
protein but not the IL2 control protein (IL2-0). Reciprocal co-
immunoprecipitation was demonstrated (see Figure S2) using
HAPP1a and an identical region of the PC1 C-tail fused to the
membrane targeting cassette, sIg.7 [22].
Analysis of PP1a Binding Determinants
To determine the region of PC1 responsible for interacting with
PP1a, IL2-PC1 fusion proteins (Figure 1B) encoding either the
membrane distal 120 amino acids (IL2-AT120, a region which
lacks the putative PP1-binding and PKA phosphorylation sites but
contains the coiled-coil) or the membrane proximal 74 amino
acids (IL2-HA74, a region which lacks the coiled-coil but contains
the putative PP1-binding and PKA phosphorylation sites) of the C-
terminal tail of PC1 were tested for their ability to co-
immunoprecipitate with PP1a. As shown in Figure 3 (also Figure
S3), both of these truncations (IL2-AT120 and -HA74) dramatically
reduced, but failed to eliminate binding of PP1a to PC1, as
compared to the longer IL2-HT193 protein. No binding of IL2-
AT120 and HA74 occurred in the absence of co-expressed PP1a
(data not shown). Weak non-specific binding of IL2-0 to PP1a
could only be detected upon over-expression of IL2-0 (see Figure
S3). These results suggest that multiple PC1 sites are involved in
PP1a binding and that PP1a interacts with the conserved PP1-
binding motif plus additional elements within the membrane distal
portion of the PC1 C-tail. It is also possible that additional PC1-
interacting proteins may be required to stabilize the interaction.
PKA-phosphorylated PC1 is a PP1a Substrate
Based on the proximity of the putative PP1-binding motifs to
the S4159 PKA phosphorylation site [24], we hypothesized that
PP1a might be able to specifically dephosphorylate PKA-
phosphorylated PC1. To test this hypothesis, the GST-HT193
fusion protein (see Figure 1B) was purified from bacteria and
phosphorylated by PKA with [c-
32P]ATP. The radiolabeled
protein was incubated with purified, recombinant PP1a or PP2B
(calcineurin) in an in vitro phosphatase assay. Following incubation,
the proteins were electrophoresed and detected by autoradiogra-
phy and immunoblotting. PC1 phosphorylation was stable over
a 2 h assay period in the absence of phosphatase. Both
phosphatases were able to dephosphorylate the generic phospha-
tase substrate p-nitrophenyl phosphate (pNPP). However, only
PP1a was able to dephosphorylate PC1 (Figure 4), suggesting that
dephosphorylation of PC1 by PP1a may be specific.
Figure 1. Polycystin-1 (PC1) sequence alignment and fusion proteins. (A) Putative protein phosphatase 1- (PP1) binding motifs (RVxF and
FxxBxB; where R can be arginine or lysine, B = basic and x = any amino acid) were identified in the C-terminal, cytosolic tail of mouse PC1 by visual
inspection of the primary amino acid sequence. Sequence alignment of a 65 amino acid region spanning the residues of interest reveals conservation
of the putative PP1-binding motifs (boxed residues, up arrows) amongst PC1 homologs of diverse species from puffer fish to mouse. The location of
the aligned sequence and putative binding motifs in the C-tail of mouse PC1 are shown schematically at the top. Additional features of the C-tail are
indicated, including the G protein binding and activation domain (gray box, labeled ‘‘G’’), the coiled-coil domain (hatched box, labeled ‘‘coil’’), and
PKA phosphorylation sites identified in PC1 (*, labeled ‘‘PKA’’). (B) DNA constructs encoding IL2-, sIg-, and GST-PC1 fusion proteins were generated for
expression in mammalian (IL2 and sIg) and bacterial cells (GST). All PC1 sequences are from mouse unless indicated. The IL2 constructs encode the N-
terminal 269 amino acids comprising the complete extracellular and transmembrane domain of the a chain of the human IL2 receptor, followed by
polylinker amino acids isoleucine-proline fused to PC1 C-tail sequences. sIg constructs have been described previously [21]. The GST constructs
encode glutathione-S-transferase followed by PC1 C-tail sequences. The HT193 portion contains the complete C-terminal 193 amino acids of mouse
PC1 (amino acids H4101 to T4293). hHT193 (bacterial expression only) contains the homologous C-terminal 193 amino acids of human (h) PC1 (amino
acids H4110 to T4302). HA74 contains the putative PP1-binding motif, G protein activation domain, and PKA phosphorylation site; but lacks the
coiled-coil domain. AT120 contains the coiled-coil domain, but lacks the features noted for the HA74 protein. The negative control, IL2-0 construct
encodes the 269 amino acids of the IL2 receptor followed by vector-encoded amino acids ILQISITLAAARACI.
doi:10.1371/journal.pone.0036798.g001
A PC1-PP1 Holoenzyme Complex
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e36798Human PC1 is Dephosphorylated by PP1a
In contrast to mouse PC1, which is phosphorylated by PKA on
S4159, human PC1 is phosphorylated by PKA at a different
position on a non-conserved serine [27]. To determine whether
PP1a dephosphorylates PKA-phosphorylated human PC1, a GST
fusion protein containing the C-terminal 193 amino acid residues
of human PC1 (GST-hHT193, Figure 1B) was tested in the in vitro
phosphatase assay. As shown in Figure 5, the GST-hHT193 fusion
protein was readily dephosphorylated by PP1a. A fusion protein in
which hS4168 (equivalent to the S4159 PKA phosphorylation site
of mouse PC1) was mutated to alanine was also readily
phosphorylated and dephosphorylated. These results confirm that
PKA phosphorylation occurs on distinct residues at different
locations in mouse and human PC1 but that both mouse and
human PC1 are dephosphorylated by PP1a.
Mutation of RVxF Residues Interferes with PC1
Dephosphorylation
Mutation of the critical hydrophobic residues in the RVxF PP1-
binding motif to alanine frequently disrupts the interaction
Figure 2. PC1 interacts with PP1a. To determine whether PC1 can interact with PP1, 293T cells were transfected with plasmids encoding
hemeagglutin (HA) epitope-tagged PP1a (
HAPP1a) and the C-terminal, cytosolic 193 amino acids of PC1 fused to the extracellular and transmembrane
portion of the IL2 receptor (IL2-HT193). Empty plasmid and an IL2 construct lacking PC1 sequence (IL2-0) were used as controls for
HAPP1a and IL2-
HT193, respectively. Lysates from the transfected cells were immunoprecipitated (IP) with anti-HA antibodies to pull down PP1a. Antibody-bound and
total fractions were resolved by SDS-PAGE and immunoblotted (IB) with anti-IL2 antibodies. Blots were then stripped and re-probed with anti-PP1a
antibody. All IL2 and sIg fusion proteins (including IL2-0 and sIg-0) used in this study migrate as doublets, presumably due to a modification of the
IL2- and sIg-portions of the fusion proteins. Asterisks are used to mark the IL2- and sIg-specific bands (or their positions were they to be present).
Solid arrows are used to indicate the position of other proteins. Different parts of this same gel image (as well as other gel images represented in this
manuscript) have been cut and rearranged for consistency and clarity. All other modifications, such as resizing or adjustments to contrast, are
performed such that all groupings of images from different parts of the same gel are treated identically. Dashed lines indicate image borders that
have been spliced together.
doi:10.1371/journal.pone.0036798.g002
Figure 3. Immunoprecipitation of PC1 truncation proteins. To determine the region of PC1 responsible for interacting with PP1a, various IL2-
PC1 fusion proteins were tested for their ability to co-immunoprecipitate with PP1a. The HA74 region of PC1 contains the putative PP1-binding motif,
but lacks the coiled-coil domain. The AT120 region of PC1 lacks the putative PP1-binding motif, but contains the coiled-coil domain. Cell lysates from
transfected 293T cells were immunoprecipitated and immunoblotted as described in Figure 2. Additional replicates of this experiment can be seen in
Figures S3. ns = non-specific band.
doi:10.1371/journal.pone.0036798.g003
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To examine this, we tested whether a series of mutations
(Figure 6A), including V4143A and F4145A in the RVxF motif,
would disrupt the ability of PP1a to dephosphorylate PC1 using
GST-HT193 fusion proteins containing these mutations in an in
vitro phosphatase assay. As seen in Figure 6B, V4143A and
F4145A mutations dramatically blocked the ability of PP1a to
dephosphorylate PC1, thus indicating the importance of the RVxF
motif in PP1a function. To determine if other residues in and
around the RVxF motif also play a critical role, those residues in
close proximity to the RVxF motif were mutated and tested
(Figure 6C). These included R4140A, H4141A, K4142A,
V4143A/F4145A, and R4144C. The R4144C mutation corre-
sponds to a human disease-associated mutation in the ‘‘x’’ residue
of the RVxF motif [31]. As a control, a V4136A mutation was also
tested. V4136 lies in close proximity to the RVxF motif and within
an amino acid sequence that is similar to but does not conform to
an RVxF motif (KVKEF; V4136 underlined).
The double mutant V4143A/F4145A blocked dephosphoryla-
tion of PC1 to an extent comparable to that of single mutants
V4143A and F4145A (Figure 6C). Mutations V4136A, R4140A,
K4142A, and R4144C did not have a significant effect on
dephosphorylation of PC1. However, mutation H4141A did have
a pronounced effect on the ability of PP1a to dephosphorylate
PC1, although not to the same extent as V4143A and F4145A.
Representative autoradiographs and immunoblots of each mutant
are shown in Figures 6B or S4A. These results demonstrate that
mutagenesis of the critical hydrophobic residues (V4143A and
F4145A) in the RVxF motif, as well as the residue in the 21
position (H4141A), interferes with the ability of PP1a to de-
phosphorylate PC1.
A number of additional mutants, some representing naturally-
occurring human polymorphisms, were tested but did not appear
to affect dephosphorylation by PP1a, suggesting that the RVxF
motif is highly specific for PP1a function. Several of these
additional mutations were located in or near the upstream FxxBxB
motif, suggesting that these residues do not function as critical
determinants of the ability of PP1a to dephosphorylate PC1.
Representative autoradiographs and immunoblots of these addi-
tional mutant proteins can be seen in Figure S4B.
We also tested the ability of ADPKD-associated mutation
F4145V to disrupt dephosphorylation of PC1. This mutation,
which affects the critical phenylalanine in the PC1 RVxF motif,
was predicted to be ‘‘probably pathogenic’’ by multiple sequence
Figure 4. Dephosphorylation of PC1 by PP1a. To determine whether PP1a can dephosphorylate PKA-phosphorylated PC1, a GST-PC1 C-tail
fusion protein (GST-HT193) was purified from bacteria, bound to GSH-agarose beads, and phosphorylated by PKA with [c-
32P]ATP. Unincorporated
32P
was removed by washing the fusion protein with an excess of cold ATP in PP1a or PP2B reaction buffer. The radiolabeled protein was then incubated
in the presence or absence of purified, recombinant PP1a or PP2B (calcineurin) for 0–2 h. Aliquots of the reaction were removed and tested for
phosphatase activity against the generic substrate p-nitrophenyl phosphate (pNPP) or frozen on dry ice in 16SDS-PAGE sample buffer to terminate
the phosphatase reaction. Terminated reactions were resolved by SDS-PAGE, and phosphorylated fusion protein was detected first by
autoradiography (AR) followed by immunoblotting.
doi:10.1371/journal.pone.0036798.g004
Figure 5. Dephosphorylation of human PC1 by PP1a. To
determine whether PP1a can also dephosphorylate PKA-phosphorylat-
ed human PC1 (hPC1), GST-hPC1 C-tail fusion proteins (GST-hHT193 and
GST-hHT193 S4168A) were purified, phosphorylated, and detected as
described in Figure 4. GST-hHT193 S4168A was used in this analysis to
be certain that phosphorylation and dephosphorylation was occurring
on a residue other than S4168, which is equivalent to the site of PKA
phosphorylation on mouse PC1 (S4159).
doi:10.1371/journal.pone.0036798.g005
A PC1-PP1 Holoenzyme Complex
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motif affect the ability of PP1a to dephosphorylate PC1, GST-HT193 fusion proteins with point mutations within and around this motif and GST-HA74
A PC1-PP1 Holoenzyme Complex
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seen in Figure 6D, this mutation also significantly reduced
dephosphorylation of PC1. This observation suggests that the
PC1/PP1 interaction and the phosphorylation of PC1 may be
clinically relevant.
Mutation of RVxF Residues does not Disrupt PC1-PP1a
Binding in vivo
Having determined that mutation of the critical hydrophobic
residues in the RVxF motif blocks dephosphorylation of PC1, we
next asked whether these mutations disrupt the binding interaction
between PC1 and PP1a in vivo. To examine this, IL2-HT193 fusion
proteins containing various RVxF mutations were tested for their
ability to co-immunoprecipitate with PP1a from lysates of co-
transfected 293T cells. None of the mutations were found to affect
the ability of PP1a to co-immunoprecipitate PC1 (see Figure S5).
These results support the idea that the interaction between PP1a
and PC1 involves multiple binding elements, and suggest that
mutations in the critical hydrophobic residues of the PC1 RVxF
motif disrupts the ability of PP1a to dephosphorylate PC1 possibly
without significantly disrupting binding.
Discussion
We have identified a putative PP1-binding motif (RVxF) in the
C-terminal, cytosolic tail of PC1 and demonstrated that PC1
interacts with and is dephosphorylated by PP1a. We have also
identified mutations in the putative PP1-binding motif of PC1 that
interfere with PP1a-mediated dephosphorylation of PC1. These
results are the first to demonstrate an interaction between PC1 and
a serine/threonine phosphatase and the first to identify the
phosphatase responsible for dephosphorylating PKA-phosphory-
lated PC1. Recently, PC1 was also shown to interact with and be
dephosphorylated by a member of the LAR-family of tyrosine
phosphatases [33]. While our studies have focused on PP1a,w e
cannot rule out the possibility that PC1 interacts with other PP1
isoforms. Many PP1 regulatory proteins do, in fact, bind to all
isoforms of PP1 [34], and we have observed binding of PC1 to the
b as well as the a isoform of PP1 (data not shown).
An interaction between PC1 and PP1a was hypothesized based
on the presence of a highly conserved RVxF motif in the C-
terminal, cytosolic tail of PC1 (Figure 1A). The interaction was
confirmed by co-immunoprecipitation of fusion proteins transient-
ly expressed in mammalian cells (Figure 2, S2). Deletion of the
putative PP1-binding domain dramatically reduced binding
(Figures 3, S3; AT120 construct). A C-terminal truncation that
left the PP1-binding motif intact also diminished binding to
a similar extent (Figures 3, S3; HA74 construct). However, neither
of these truncations failed to completely eliminate binding. We
also observed that RVxF mutations that interfered with de-
phosphorylation of PC1 did not significantly diminish the ability of
PC1 to be co-immunoprecipitated with PP1a (Figure S5).
A possible explanation for these observations is that PC1
contains multiple PP1-binding determinants. In some cases,
mutation of critical residues within the RVxF domain of known
PP1-regulatory proteins can completely disrupt binding [30]. In
other cases, these mutations have no obvious effect on binding to
PP1 when expressed in the context of a large polypeptide or full-
length protein, but can disrupt binding between PP1 and
interacting short peptide regions derived from the full-length
protein [6,29]. Thus, PP1 regulatory proteins are likely to have
multiple sites of interaction that facilitate stable interactions and
help dictate the unique substrate specificity for a given PP1
holoenzyme [34,35]. Consistent with this, other PP1-interacting
motifs have been identified, including the myosin phosphatase N-
terminal element (MyPhoNE) [8,36], the SILK motif [8,37,38,39],
and the FxxBxB motif [6,7]. Of these, the MyPhoNE and SILK
motifs have been identified in many PP1-regulatory proteins,
although they are not present in PC1. PC1 does contain two
FxxBxB motifs in close proximity to the RVxF motif. However,
mutations that affected these residues did not disrupt dephos-
phorylation. Furthermore, these motifs are localized in the IL2-
HA74 protein, which binds to PP1a poorly. While we cannot rule
out contributions of the FxxBxB motifs to the PC1-PP1a
interaction, it seems likely that if additional binding determinants
are present in the C-tail of PC1, they reside distal to the RVxF
motif in the C-terminal 120 amino acids.
Another potential explanation is that the interaction between
PC1 and PP1a is not direct. Numerous binding partners of PC1
have been identified, with a number of interactions occurring via
the PC1 coiled-coil domain [40]. Given that deletion of the region
of PC1 containing the coiled-coil dramatically reduced binding to
PP1a, it seems possible that additional proteins that interact via
the PC1 coiled-coil might stabilize the interaction between PC1
and PP1a.
The ability of PC1 to interact with PP1a raised the possibility
that PP1a may be the phosphatase responsible for depho-
sphorylating PKA-phosphorylated PC1. We confirmed that
PP1a dephosphorylates PKA-phosphorylated PC1 in an in vitro
phosphatase reaction (Figure 4). This reaction appears to be
specific for PP1a, since PP2B was incapable of dephosphorylating
PC1, despite having higher activity toward a generic substrate.
Furthermore, mutation of critical hydrophobic residues (V4143
and F4145) in the RVxF PP1-binding motif and H4141 in the -1
position relative to the motif disrupted dephosphorylation of PC1
(Figure 6). Thus, PC1 appears not only to be a PP1 regulatory
protein, but also a PP1 substrate. An ADPKD-associated mutation
affecting F4145 (F4145V) also disrupted dephosphorylation of
were analyzed in an in vitro kinase/phosphatase assay as described in Figure 4. The amount of phosphorylated protein (relative to input material at
the start of the reaction) remaining after 2 h in the presence or absence of PP1a was determined by autoradiography and immunoblotting. Following
detection of the fusion proteins, membranes were stripped and re-probed for the presence of PP1a. (A) Sequence of wild type (WT), and mutant RVxF
constructs of PC1. The primary amino acid sequence spanning the various sites of mutagenesis is shown. The identity of the mutated residue is
shown at left and underlined in the primary sequence. The RVxF motif is in bold. (B) Representative autoradiographs and immunoblots showing
phosphorylation and total protein levels of GST-HT193 WT, V4143A, and F4145A PC1 fusion proteins. (C) Summary of the effects of PC1 mutations on
PP1a-mediated dephosphorylation of PC1. On average, approximately 67% of WT input material was dephosphorylated over the 2 h assay period.
Data (mean 6 SE) represent the percent dephosphorylation of PC1 constructs by PP1a, relative to dephosphorylation of WT PC1 (set to 100%). n=6
for WT and n=5 for mutant constructs. *P,0.05 and **P,0.01, compared to the effect of PP1a on WT PC1, determined by one-way ANOVA and the
Dunnett multiple comparison post-test. Representative autoradiographs and immunoblots for GST-HT193 V4136A, R4140A, H4141A, K4142A, R4144C,
and V4143A/F4145A are shown in Figure S4A. Representative autoradiographs and immunoblots for additional mutants which lacked obvious
defects in PP1a dephosphorylation are shown in Figure S4B. (D) Summary and representative autoradiographs and immunoblots showing
phosphorylation and total protein levels of GST-HT193 WT and F4145V PC1 fusion proteins. Data (mean 6 SE) represent the percent
dephosphorylation of PC1 constructs by PP1a, relative to dephosphorylation of WT PC1 (set to 100%). n=6 for WT and F4145V. ***P,0.001,
compared to the effect of PP1a on WT PC1, determined by unpaired t test.
doi:10.1371/journal.pone.0036798.g006
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ylation of PC1 may be clinically relevant. Interestingly, both
human and mouse PC1 are substrates for PP1a (Figure 5), despite
the fact that PKA phosphorylation occurs at different sites in the
two proteins.
The ability of the H4141A mutation to interfere with the
dephosphorylation of PC1 (Figure 6) is consistent with a recently
published detailed analysis of the RVxF motif and surrounding
amino acids [8]. This analysis of over 140 validated PP1-
interacting proteins suggests that the binding motif should be
redefined as RRVxF to reflect the prevalence of a basic residue in
the -1 position relative to the currently accepted RVxF motif.
While histidine is under-represented at this position in the
compiled sequence of validated PP1-interacting proteins, histidine
does have the potential to behave as a basic residue. Furthermore,
H4141 of PC1 lies in a cluster of basic residues which includes
K4135, K4137, R4140, and K4142. Interestingly, amongst the
PP1-interacting proteins analyzed, there seems to be some
tolerance for alanine in the second but not the first basic residue
position of the expanded RRVxF binding motif (RAVxF,
prevalence of ,7.5% vs. ARVxF, never represented). Consistent
with this observation, mutation H4141A (ARVxF) but not
K4142A (RAVxF) had a statistically significant effect on PP1a-
mediated dephosphorylation of PC1. Our data would suggest that
the presence of a basic residue in the first basic position is more
important than its presence in the second. Also of interest, PC1
contains lysine and arginine residues in the –4 and –1 positions of
the expanded RRVxF motif, respectively, which are the residues
most frequently represented at these positions in the compiled
sequence of validated PP1-interacting proteins [8]. Thus, the
amino acid sequence in and around the putative PP1-binding
motif of PC1 is actually very similar to the amino acid sequence of
PP1-binding domains found in a large number of validated PP1-
regulatory proteins.
The proximity of the PKA phosphorylation site to the PP1-
binding motif is intriguing. Perturbation of the sites of interaction
between PP1 and its regulatory proteins by changes such as
phosphorylation can dramatically alter the activity of the
holoenzyme [35,41,42,43]. For example, the PP1-regulatory
proteins dopamine- and cAMP-regulated phosphoprotein with
molecular weight 32 kDa (DARPP-32) and inhibitor-1 are both
inhibitors of PP1 activity. These regulatory proteins bind PP1
equally well regardless of their phosphorylation state, but are poor
inhibitors in the unphosphorylated state. Upon phosphorylation,
the IC50 of these inhibitors increases by 1,000 fold, presumably by
forming a pseudo-substrate complex with the phosphatase [1]. In
contrast, the negative regulation of PP1 exerted by another PP1
regulatory protein, nuclear inhibitor of protein phosphatase 1
(NIPP1), is relieved by PKA and casein kinase 2 phosphorylation
of NIPP1 [30].
PP1-regulatory proteins that are also substrates can integrate
competing signals from the phosphorylating kinase and PP1. A
prime example of this mode of regulation is that of the kinase
Nek2, a PP1-regulatory protein that induces centrosome splitting.
Nek2 is activated by autophosphorylation, and is thought to
trigger centrosome splitting by phosphorylating cohesion proteins
such as C-Nap1 [44]. Nek2 and C-Nap1 are likely depho-
sphorylated by associated PP1, whose activity is modified by ATM
and CDKs [2]. Thus, centrosome splitting appears to be
controlled by multiple inputs converging on the ability of the
PP1-regulatory protein and substrate Nek2 to remain phosphor-
ylated. We speculate that a PC1-PP1a holoenzyme complex may
function in a similar manner.
In Figure 7, we present a model of PC1-PP1 holoenzyme
function whereby signaling events downstream of PC1 are
regulated by the competing actions of PP1 and cellular kinases
acting on PC1 itself or other, putative substrates of the
holoenzyme. For example, PP1 may serve as a molecular switch
that antagonizes PC1-mediated signaling initiated by events such
as PKA-mediated phosphorylation of PC1. Alternatively, PP1 may
regulate the phosphorylation of PC1-interacting proteins such as
PC2, a protein whose localization and activation are known to be
affected by phosphorylation [45,46,47,48]. In our model, we
predict that perturbation of PC1-PP1 holoenzyme function, either
by complete loss of PC1 or by PC1 mutations that affect the
activity of PP1 in complex with PC1 (e.g. RVxF mutations,
Figure 6), would lead to disregulated phosphorylation and cell
signaling that could potentially initiate or exacerbate cystogenesis.
In summary, we have identified PC1 both as a regulatory subunit
and as a substrate for PP1a. We propose that PC1 and PP1a form
a holoenzyme complex in which the two proteins stably interact
and are poised to dephosphorylate substrates required for normal
cellular functions. The identification of PC1 mutations that
interfere with the activity of PP1a in complex with PC1 should
facilitate efforts to understand the role of PP1a in PC1-mediated
signaling as well as the role of PKA phosphorylation in the
function of PC1.
Supporting Information
Figure S1 Pkd1 construct and primer sequences. (A)
Coding and 39 non-coding sequence of pcDNA1.1/AMP IL2-
HT193: The ATG start codon is at the 59 end followed by IL2
sequence. The polycystin-1 (PC1) encoding region of IL2-HT193 is
in bold. Vector sequences are in lower case. EcoRI (GAATTC)
and NotI (GCGGCCGC) restriction sites are underlined. (B) PCR
Figure 7. Model of PC1-PP1a holoenzyme function. In this model we speculate that PP1 regulates the phosphorylation status of PC1 and PC1-
interacting proteins, and that disruption of the PC1-PP1 holoenzyme complex may lead to altered signaling and cystogenesis due to misregulation of
protein phosphorylation.
doi:10.1371/journal.pone.0036798.g007
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e36798primer sequences: *the AT reverse primer is complementary to
both human PKD1 and mouse Pkd1; **the bold underlined base in
primer sequence human (h) HT-forward introduces a silent
mutation into the hHT193 sequence. This mutation was necessary
to disrupt secondary structure in the original primer sequence,
which prevented efficient priming. (C) Sequence of mutant PKD1
clones: The sites of mutation within mouse Pkd1 and human (h)
PKD1 are shown. Mutated residues are in bold; affected codons
are underlined.
(DOCX)
Figure S2 PP1a immunoprecipitates with PC1. 293T cells
were transfected with plasmids encoding hemeagglutin (HA)
epitope-tagged PP1a (
HAPP1a) and the C-terminal, cytosolic 193
amino acids of PC1 fused to the membrane targeting cassette,
sIg.7 [22]. Empty plasmid and a sIg construct lacking PC1
sequence (sIg-0) were used as controls for
HAPP1a and sIg-HT193,
respectively. Lysates from the transfected cells were immunopre-
cipitated (IP) with protein A/G+ agarose to pull down sIg-
constructs. Bound and total fractions were resolved by SDS-PAGE
and immunoblotted (IB) with anti-HA antibodies to detect
HAPP1a, then stripped and re-probed with anti-human IgG Fc-
alkaline phosphatase conjugated antibody to detect sIg-constructs.
While some
HAPP1a could be detected in the sIg-0 bound
fractions, we consistently observed enrichment of
HAPP1a when
precipitated with sIg-HT193.
(TIF)
Figure S3 PC1 immunoprecipitates with PP1a. Panels A,
B, and C are replicate co-immunoprecipitation experiments (see
Figure 2). Note in A and B that there is less PP1a present in the
IL2-HT193 bound fraction as compared to all other lanes, and yet
there is significantly more IL2-HT193 co-immunoprecipitated than
IL2-HA74, -AT120,o r20. Also note that more IL2-HT193 can be
detected in the bound fraction of B despite dramatic over-
expression of IL2-HA74 as demonstrated in the total fraction. In A
and C, some IL2-0 can be detected in the bound fraction.
However, the amount of IL2-0 in the bound fraction is never
greater than that of any PC1 protein, and the amount of IL2-
0 present in the total fraction is significantly greater than the
amount of any PC1 protein. No IL2-0 was detected in the bound
fraction of B. ns = non-specific band.
(TIF)
Figure S4 Representative autoradiographs and immu-
noblots of in vitro kinase/phosphatase assays. (A)
Analysis of PC1 mutants V4136A, R4140A, H4141A, K4142A,
R4144C, and the double mutant V4143A/F4145A was conducted
as described in Figure 5. (B) Additional PC1 mutants as well as
PC1 truncation protein HA74 were analyzed by autoradiography
and immunoblotting as described in Figure 5. Mutations L4122D,
R4125L, R4126G, R4126T, and R4128L are either naturally
occurring PKD associated mutations and/or lie in or near the
upstream FxxBxB site in PC1 (Figure 1A) [6,7,31,49]. In addition,
we had previously demonstrated that mutations L4122D,
R4126G, and R4126T inhibit heterotrimeric G protein signaling
(see Magenheimer, B. S., et al. (2002) J Am Soc Nephrol 13, 18A F-
FC085). Q4215P is a PKD associated mutation that interrupts the
coiled-coil domain of PC1 [50]. Y4117D was examined as it is
a potential site of tyrosine phosphorylation [17]. GST-HA74 was
examined because IL2-HA74 co-immunoprecipitates poorly with
PP1a from lysates of co-transfected 293T cells (Figure 3).
(TIF)
Figure S5 RVxF mutations fail to disrupt the PC1-PP1a
interaction. To determine whether RVxF mutations disrupt
binding between PC1 and PP1, 293T cells were transfected and
immunoprecipitated as described in Figure 2 but with wild type
and RVxF-mutated IL2-HT193 fusion proteins. RVxF mutations
V4143A and F4145A failed to appreciably decrease binding with
HAPP1a.
(TIF)
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